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Purpose: Glycogen rich clear cell carcinoma (GRCC) of the breast is a rare sub-
type of invasive ductal carcinoma and involves a poor prognosis. In the literature, 
less than 150 cases have been reported. Many researchers have attempted to charac-
terize GRCC according to electron microscope, flow cytometry, or clinical data. 
However, an organized study of the immunophenotype of GRCC has yet to be re-
ported. Materials and Methods: Here, we present three cases of GRCC and their 
immunohistochemical profiles. Results: Histologically, all three cases contained 
periodic acid stain (PAS) positive and d-PAS labile granules in their clear cyto-
plasm. Case I showed positivity for only estrogen receptor (ER) and c-erbB2. Case 
II exhibited positivity for progesterone receptor and negativity for ER and c-erbB2. 
Case III presented with triple negative invasive carcinoma. The expression pattern 
of E-cadherin was concordant with epidermal growth factor receptor and c-kit, but 
discordant with ki-67. Among these three cases, p53-positive cases exhibited a low 
proliferative index (ki-67: 15%), while p53-negative cases showed a high prolifera-
tive index (ki-67: 50-60%). Conclusion: In conclusion, the immunophenotype of 
GRCC is not uniform, but is similar to that of conventional ductal carcinoma.
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INTRODUCTION
Glycogen rich clear cell carcinoma (GRCC) of the breast is known as a rare sub-
type of invasive ductal carcinoma, and involves a poor prognosis. It was first de-
scribed by Hull, et al.1 in 1981. Since then, fewer than 150 cases have been report-
ed. Many researchers have attempted to characterize GRCC, according to, electron 
microscope (EM),1,2 flow cytometry,3 or clinical data,4-6 the results of which have 
been summarized in Table 1.
Hull, et al.1 confirmed intracytoplasmic glycogen of GRCC by EM and stated 
that the H&E and EM features of GRCC were very similar to the morphology of 
13-week old fetal developing mammary gland. In diagnosing GRCC, tumor cells 
that contain abundant fine glycogen granules in their clear cytoplasm, are stained 
by periodic acid stain (PAS), but not stained by diastase-periodic acid stain (d-
PAS). The incidence of GRCC is estimated to be 1 to 3% of breast carcinoma. 
Opinions differ with among researchers concerning the prognosis of GRCC, rang-
ing from favorable to unfavorable.2-6 Immunohistochemical (IHC) staining for es-
trogen receptor (ER) is usually positive. However, IHC for progesterone receptor 
Immunophenotypes of Glycogen Rich Clear Cell Carcinoma
Yonsei Med J   http://www.eymj.org   Volume 53   Number 6   November 2012 1143
cases found during the last 10 years. One case was lost to 
follow up after diagnosis by biopsy. The ages at diagnosis 
were 49 to 69 years old and follow up data were 14 months 
and 18 months. They were currently disease-free states. 
They were treated with total and partial mastectomy fol-
lowed by chemotherapy and radiation therapy. 
Immunohistochemical (IHC) staining
The antibodies used to conduct this study are listed in Table 
3. Paraffin blocks were sectioned to a thickness of 4 um 
and tissues were attached on silane coated slides. The slides 
(PR) and c-erbB2 has been shown to vary.5-8 Other than 
hormone receptors, no organized study concerning the im-
munophenotype of GRCC has been published. Here, we 
present three cases of GRCC and their immunohistochemi-
cal profiles. 
MATERIALS AND METHODS
　　　
Clinical data
Table 2 summarizes the clinical data. There were only three 
Table 1. GRCC in Previous Publications 
Fisher, 
et al.4
Hull, et al.1,2
Toikkanen 
and Joensuu3
Hayes, et al.5
Kuroda, 
et al.6
Varga, et al.7
Akbulut, 
et al.8
Numbers of cases 45 10 6 21 20 12 37
Incidence (%) 2.9 1.0 1.4 N/A 2.8 N/A N/A
Age (mean) N/A 59.4 58.3 54 52 66.9 52
Mass size (cm) N/A 2-6.5 4-8 1-8 1-6.5 3.7 N/A
TNM stage N/A T1N0-T3N1 T2N0-4N1 T1N0-T3N1 N/A N/A N/A
F/U months N/A 1-175 7-75 2-84 16-72 N/A N/A
Operation name (%) N/A
RM (60), SM (10),  
  MRM (20), Ex (10)
RM (66), 
  MRM (33)
MRM (77), 
  Ex (23)
RM (65) N/A N/A
Post-op treatment (%) N/A N/A RT (83)
RT (23), 
  Chx (8)
RT (25) N/A N/A
Prognosis Poor Poor Poor Same Same Same Poor
Flow cytometry (%)
    DNA index N/A N/A
100 (>1.3)  
  ND
N/A N/A N/A N/A
    S-phase fr. N/A N/A 19.20 N/A N/A N/A N/A
ER N/A N/A N/A 67% (6/9) 35% (7/20) 75% (9/12) 62% (16/37)
PR N/A N/A N/A 0% (0/3) 30% (6/20) 33% (4/12) 43% (16/37)
C-erbB2 N/A N/A N/A N/A 20% (4/20) 33% (4/12) 44% (16/36)
Her2-Fish amplification N/A N/A N/A N/A N/A 25% (3/12) N/A
P53 N/A N/A N/A N/A N/A N/A 58% (21/36)
Ki-67 index N/A N/A N/A N/A N/A N/A 20%
N/A, not available; F/U, follow up; RM, radical mastectomy; SM, simple mastectomy; MRM, modified radical mastectomy; Ex, excision; RT, radiation 
therapy; Chx, chemotherapy; fr, fraction; ND, non-diploid; ER, estrogen receptor; PR, progesterone receptor; GRCC, glycogen rich clear cell carcinoma.
Table 2. Clinical Findings 
Case 1 Case 2 Case 3
Age 57 49 69
Ass. Lesion FCD FCD N/A
Mass size (mm) 23 12 N/A
pTNM T2N0M0 T1N0M0 N/A
Location RUL LUM N/A
Last F/U 2011-11-06 2011-12-16 N/A
F/U mos 18 14 N/A
Op name TM/c SLNB PM/c SLNB N/A
Post-op Tx 6th AC 4th AC+postRT N/A
FCD, fibrocystic change; RUL, right upper lateral; LUM, left upper medial; F/U, follow up; TM/c SLNB, total mastectomy with sentinel node biopsy; PM/c 
SLNB, partial mastectomy with sentinel node biopsy; AC, cyclophosphamide+adriamycin; RT, radiation therapy; N/A, not available.
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receptor (AR), p53, p63, and ki-67; cytoplasmic positivity 
for gross cystic disease fluid protein 15 (GCDFP-15); nu-
clear and cytoplasmic positivity for c-kit and galectin3; and 
cytoplasmic membrane positivity for c-erbB2, e-cadherin, 
and epidermal growth factor receptor (EGFR). Additional-
ly, a proportional index was evaluated to describe the per-
centage of positivity for a few of the antibodies, including 
hormone receptors (ER, PR, and AR) and p53.
 
RESULTS
 
Three patients were diagnosed with invasive glycogen rich 
clear cell carcinoma from 2000 to 2011 at our institution. On 
gross examination, GRCCs appeared as well-circumscribed, 
irregular and solid masses. No difference was found in com-
parison to conventional invasive ductal carcinoma. Micro-
scopically, GRCCs consisted of solid nests of clear cells 
with fine meshwork vasculatures. The individual cancer 
cells showed clear cytoplasm with fine granules and rela-
tively low nuclear and cytoplasmic ratio. Nuclei were 
were baked at 60°C for 60 minutes and washed in xylene 
for deparaffinization. For hydration of sections, the slides 
were bathed in gradient alcohol and distilled water. The anti-
gen retrieval step was followed by boiling slides in 10 mM 
citrate buffer (pH6.0) for 10 minutes. Afterwards, the slides 
were immersed in 3% H2O2 for 15 minutes to block intrinsic 
hydro-peroxidase activity. The slides were incubated with 
primary antibodies for 2 hours at room-temperature, fol-
lowed by incubation with secondary antibody (Enzyme-con-
jugated polymer, EnVision Detection kit, Denmark) for 15 
minutes at room-temperature. A NovaRED substrate kit 
(VECTOR Laboratory, Burlingame, CA, USA) was ap-
plied to develop color following the manufacture’s proto-
col. Harris hematoxylin was used for counter staining. 
Interpretation of immunohistochemical staining
IHC slides were evaluated by light microscopy. The scoring 
intensity of IHC staining was based on a three-grade sys-
tem; 1 positive (weak), 2 positive (intermediate) and 3 posi-
tive (strong). The grade intensity of positive stainig was as-
sessed as follows; nuclear positivity for ER, PR, androgen 
Table 3. Antibodies Used in This Study
Antibody Clone Dilution Source
ER 6F11/16 1 : 500 Novocastra, UK
PR 16 1 : 1000 Novocastra, UK
HER-2/neu 4B5 Prediluted Ventana, USA
p53 DO-7 1 : 2000 Novocastra, UK
p63 4A4 1 : 1000 DAKO, Denmark
Ki-67 MIB-1 1 : 800 DAKO, Denmark
E-cadherin 36B5 1 : 50 Novocastra, UK
AR 4R441 1 : 100 Lab vision Corp.
EGFR 3C6 1 : 15 Ventana, USA
GCDFP-15 23A3 1 : 100 Neomarkers
C-kit Polyclonal 1 : 100 DAKO, Denmark
Galectin3 9C4 1 : 400 Novocastra, UK
ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; EGFR, epidermal growth factor receptor; GCDFP-15, gross cystic disease fluid 
protein 15.
Fig. 1. Histologic features of GRCC. (A) Tumor shows solid nests of clear cells with fine meshwork vasculatures (×100). (B) The individual cancer cells have 
clear cytoplasm with fine granules, low N-C ratio, wrinkled nuclei, and prominent nucleoli (×400). (C) The granules in tumor cells are stained with PAS (×400 
and ×1000 in box). (D) The granules are not stained with d-PAS (×400 and ×1000 in box). GRCC, glycogen rich clear cell carcinoma; PAS, periodic acid stain.
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three groups. The first group of proteins shared the same im-
muno-scoring and were related to cell surface molecules, in-
cluding EGFR, c-kit, and E-cadherin. The second group was 
related to hormone receptors, including ER and AR. The 
third group was characterized by p53 related proliferation. 
EGFR and c-kit are both cell surface receptors important 
to the PI3K through AKT and RAS to MAPK signal trans-
duction pathways, and have been shown to be involved in 
cell survival and proliferation,9,10 Double expression of 
EGFR and c-kit in breast carcinoma is known as a predic-
tive marker of poor prognoses.11 Among our cases, ki-67, 
marker of cell proliferation, was also synchronously up-
regulated along with up-regulation of EGFR and c-kit. Tak-
en together, in predicting poor prognoses, expression of 
both EGFR and c-kit sould be associated with high mitotic 
index. In our GRCC cases, case 1 was both EGFR and c-kit 
negative with a low mitotic index, while the other two (cas-
es 2 and 3) were positive for both with a high mitotic index. 
The expression pattern of EGFR and c-kit was concordant 
with E-cadherin and discordant with ki-67. Most studies on 
E-cadherin have focused on lobular carcinoma.12 The role 
of E-cadherin in ductal carcinoma is still unknown. The 
function of E-cadherin is considered related with cell adhe-
sion molecules; thus, loss of expression would be associat-
ed with a high incidence of invasion and metastasis. A few 
researchers stated that up-regulation of E-cadherin would 
be associated with a better prognosis in invasive ductal car-
cinoma.13 However, the mechanism is unclear. 
P53 is a well known nuclear protein that participates in 
cell proliferation. In benign conditions, p53 is not detectable 
by IHC staining. Cancer progression demonstrates accumu-
lations of non-functional and non-degraded p53 protein in 
somewhat wrinkled. Nuclear membranes were irregularly 
thickened and their nucleoli were prominent. All of them 
contained PAS positive and d-PAS labile granules in the cy-
toplasm of more than 90% of tumor cells (Fig. 1). Mucin 
was not detected upon alcian blue and mucicarmin staining. 
Tests for GCDFP-15 were negative. The tumors were, there-
fore, considered to involve no apocrine differentiation.
The three cases revealed three different immuno-pheno-
types (Table 4). Case 1 showed positivity for ER and negativ-
ity for PR. Case 2 was positive for PR, but negative for ER. 
Case 3 presented with triple negative invasive carcinoma. All 
three cases were negative for c-erbB2. Androgen receptor 
was positive in the ER positive case 1. EGFR, E-cadherin, 
and CD117 (c-kit) showed positivity in two cases (cases 2 
and 3). Among these three cases, p53-positive case exhibited 
a low proliferative index (ki-67: 15%), while p53-negative 
cases showed high proliferative index (ki-67: 50-60%). 
DISCUSSION
GRCC is a very rare entity that exhibits distinctive clear 
cells with intracytoplasmic glycogen. However, no trials 
have been conducted to reveal the distinct characteristics of 
GRCC, including clinical behavior, biologic features, im-
munophenotypes, and genetics.2-6,8 
Because of the rarity, we accumulated only three cases of 
GRCC out of more than 2000 cases of carcinoma over the 
last 10 years. Twelve different antibodies were evaluated in 
the three cases, the immunophenotypes of which prove not 
to be uniform. Based on immuno-scoring, we were able to 
characterize the expression patterns of targeted proteins into 
Table 4. Immunophenotypes of GRCC
Case 1 Case 2 Case 3
ER 100%/2 pos Neg Neg
PR Neg 60%/2 pos Neg
C-erbB2 1 pos Neg Neg
P53 80%/2 pos Neg Neg
P63 Neg Neg 5%
Ki-67 15% 40% 60%
E-Cad No loss Gain (3 pos) Gain (3 pos)
AR 90%/2 pos Neg Neg
EGFR Neg 3 pos 2 pos
GCDFP-15 Neg Neg Neg
C-kit Neg 2 pos 1 pos
Galectin3 2 pos 1 pos Neg
ER, estrogen receptor; PR, progesterone receptor; E-Cad, E-cadherin; AR, androgen receptor; EGFR, epidermal growth factor receptor; GCDFP-15, gross 
cystic disease fluid protein 15; pos, positive; neg, negative.
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nuclei, resulting in immuno-positivity of p53 protein. Mutat-
ed p53 protein cannot suppress genetic errors leading to can-
cer development. Nevertheless, p53 over-expression has 
been considered a poor prognostic marker and accompanied 
by a high mitotic index in invasive ductal carcinoma.14 Our 
three cases demonstrate just the opposite. Case 1 showed 
strong positivity for p53 with low mitotic index, while cas-
es 2 and 3 showed negativity for p53 with high mitotic in-
dex. These findings support the possibility of an association 
of cell proliferation with the signal transduction of surface 
molecules (EGFR, c-kit and E-cadherin), not with mutation 
of p53 protein, in GRCC.
Case 3 presented as a triple negative carcinoma and also 
expressed p63 protein. Case 3 was a basal-like breast can-
cer and was predicted to involve a poor prognosis. Increased 
proliferative activity as determined by ki-67 (60%) and over-
expression of EGFR supported the possibility of a poor 
prognosis. The diagnosis of this case was confirmed only 3 
months prior to the preparation of this manuscript; there-
fore, follow up data are currently not available. Based on 
IHC results, this case will require continued attention for 
future treatment. Presently, researchers agree that if GRCC 
is comparable to the conventional ductal carcinoma of the 
same TNM stage, the prognosis of the two types of carcino-
mas would be the same.7 
As only three cases were available for study, the drawing 
of any conclusions would be limited. However, these cases 
did reveal different IHC characteristics for GRCC. We be-
lieve that the cases presented herein substantiate a need to 
re-examine the general features of GRCC. While the immu-
nophenotypes of GRCC were not uniform, they appeared to 
be very similar to conventional ductal carcinoma.
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